Lymphoma

The safety profile of ibrutinib/venetoclax in the phase 3 SYMPATICO trial was consistent with the known profiles for each individual agent.

As MZL is such a rare subtype of lymphoma, it can be hard to find or begin trials geared specifically toward this population.

The toxicity profile of loncastuximab tesirine plus rituximab was consistent with prior clinical trials assessing each agent as monotherapy.

Potential contributing factors of marginal zone lymphoma (MZL) were highlighted in a recent discussion with James R. Cerhan, MD, PhD.

Anakinra prophylaxis did not significantly decrease the incidence or severity of CRS or ICANS in patients with LBCL treated with liso-cel.

Juan Alderuccio, MD, discussed treatment strategies for MZL, particularly as they relate to quality of life, and the role of prognosis models on treatment.

Julie M. Vose, MD, MBA, answered questions about the significance and potential impact of MZL Workshop.

Data from the ECHELON-3 trial support the approval of the brentuximab vedotin combo in relapsed/refractory B-cell lymphoma.

A pathologist discusses the challenges of diagnosing nodal MZL, including its lack of specific defining characteristics.

In the phase 2 TRANSCEND FL trial, lisocabtagene maraleucel met its primary end point of overall response rate in patients with marginal zone lymphoma.

Marginal Zone Lymphoma experts discussed recent advancements in all areas of MZL, while calling attention to gaps in knowledge in the 2024 MZL Scientific Workshop.

Completion of the phase 1 first-in-human trial revealed that iPSC-derived CAR natural killer cell therapy has potential for development across oncology.

Thomas Habermann, MD, discusses the significance of the MZL Workshop and its contributions to advancing research and improving outcomes.

Julie M. Vose, MD, MBA, discussed MZL research and future directions in the February Letter to Readers.

The TRANSCEND FL trial showed that liso-cel elicited an ORR of 97.1% and a complete response rate of 94.2% in patients with follicular lymphoma.

Researchers from the University of Wisconsin, Cornell, and a consortium of other institutions conducted a retrospective analysis on CD19-directed CAR T-cell therapy for R/R T-cell/histiocyte-rich LBCL.

Select patients may be eligible to continue treatment with tabelecleucel or ATA3219 in accordance with study protocols.

The CRL did not identify any deficiencies related to the manufacturing, efficacy, or safety outlined in the BLA, and no new clinical trials were requested.

Brentuximab vedotin, lenalidomide, and rituximab yielded a median OS of 13.8 months and a median PFS of 4.2 months in the phase 3 ECHELON-3 trial.

The FDA has approved acalabrutinib in previously untreated MCL based on results from the phase 3 ECHO trial.

Brad S. Kahl, MD, and Tycel Phillips, MD, discussed the use of acalabrutinib plus bendamustine and rituximab for patients with untreated MCL.

Here are 3 things you should know about immunotherapy in diffuse large B-cell lymphoma.

Results from the CLOVER WaM trial saw a clinical benefit rate of 98.2% in patients with Waldenström Macroglobulinemia treated with Iopofosine I 131.

Phase 3 data support tafasitamab plus lenalidomide/rituximab as a potential new standard of care in patients with relapsed/refractory follicular lymphoma.

Autologous transplant did not confer significantly improved overall survival regardless of induction intensity in a phase 3 trial.

Pirtobrutinib sustained BTK inhibition and improved progression-free survival in patients with CLL and SLL, data from the phase 3 BRUIN CLL-321 trial showed.

Glofitamab with polatuzumab vedotin benefited patients with high-grade B-cell lymphomas and who failed prior CAR T-cell therapy.

Phase 2 data support epcoritamab monotherapy as a promising chemotherapy-free option for older patients with newly diagnosed LBCL.

Findings from the phase 1/2 CaDAnCe-101 trial showed that promising ORRs in R/R WM and R/R CLL/SLL stemmed from BGB-16673 treatment.

For patients with CLL and SLL, sonrotoclax with zanubrutinib yielded high rates of overall response in the phase 1/1b BGB-11417-101 study.